Congress Program
>
Meetings > Congress Program
March 29 (Thursday)
| Time | VISTA 1 | VISTA 2 | VISTA 3 | ||
|---|---|---|---|---|---|
| 07:30 | Registration | ||||
| 08:00 | Opening Remark (Place: Vista 1) | ||||
| 08:00 - 09:00 | Oral Presentation 01 | Oral Presentation 02 | Oral Presentation 03 (KOR) | ||
| 09:00 - 10:00 | Educational Session 01 (KOR) | Education Session 02 (KOR) | Education Session 03 (KOR) | ||
| Multiple Myeloma | Typical and atypical Chronic Myelogenous Leukemia | Thrombotic Microangiopathy | |||
| Monoclonal Gammopathy of Renal Significance (Jung Eun Lee, Sungkyunkwan Univ, Samsung Medical Center, Korea) |
Optimal First-line Treatment of Chronic Phase CML (Kyoung Ha Kim, Soonchunhyang Univ., Korea) |
Childhood aHUS (Hae Il Cheong, Seoul National Univ., Korea) |
|||
| Smoldering Multiple Myeloma (Byung-Su Kim, Hallym Univ., Korea) |
Update on the Treatment of CML in Children (Jae Wook Lee, The Catholic Univ., Korea) |
Adult aHUS (Youngil Koh, Seoul National Univ., Korea) |
|||
| Next Generation Sequencing in Multiple Myeloma (Miyoung Kim, Hallym Univ., Korea) |
BCR-ABL1 Negative Hematologic Neoplasms; Diseases that are Similar to but Different from CML) (Hawk Kim, Gachon Univ., Korea |
Management of TTP (Doyeun Oh, CHA Univ., Korea) |
|||
| 10:00 - 10:20 | Coffee Break | ||||
| 10:20 - 11:40 | Scientific Session 01 | Scientific Session 02(KSH-KAI Joint) | |||
| Single Cell Genomics | Cancer Immunology | ||||
| Single Cell Genome Analysis in Human Cancers (Woong-Yang Park, Sungkyunkwan Univ., Korea) |
Immune Checkpoint Inhibition in Hematologic Malignancy - Focusing on Multiple Myeloma (Yoon Seok Choi, Chungnam National Univ., Korea) |
||||
| Characteristics of Tumor Infiltrating Lymphocytes Revealed by Single Cell RNA Sequencing (Zemin Zhang, Peking Univ., China) |
A New Antigen Presenting Cell based Therapeutic Cancer Vaccine (Chang-yuil Kang, Seoul National Univ., Korea) |
||||
| Dissecting the Cellular and Genetic Composition of Pediatric Leukemias by Single-Cell Genomics (Charles Gawad, St. Jude Children's Research Hospital, USA) |
Chimeric Antigen Receptor-engineered Natural Killer Cell Immunotherapy for Cancer (Kyung-Nam Koh, Univ. of Ulsan, Korea) |
Post-transplant Immunotherapy with WT1-specific CTLs for High-risk AML (Tai-Gyu Kim, The Catholic Univ., Korea) |
|||
| 11:40 - 11:50 | Break | ||||
| 11:50 - 12:50 | Oral Presentation 04 | Oral Presentation 05 | Oral Presentation 06 | ||
| 12:50 - 13:00 | Break | ||||
| 13:00 - 14:00 | [Luncheon] Satellite Symposium 01 KYOWA KIRIN |
[Luncheon] Satellite Symposium 02 NOVARTIS |
[Luncheon] Satellite Symposium 03 HANDOK |
||
| Updated Febrile Neutropenia Management Won Seog Kim (Sungkyunkwan University School of Medicine, Korea) |
It's Time We Go Deeper Pierre Laneuville (McGill University Health Centre Montreal, Canada) |
Complement Mediated Glomerular Disease(Focusing on aHUS): Everything Has Changed in the Last 10 Years but Still a Lot to Do Giuseppe Remuzzi (Mario Negri Institute for Pharmacological Research, Italy) |
|||
| 14:00 - 15:20 | Plenary Lecture 01 | ||||
| Precision Hematology in Genomics Era | |||||
| Precision Medicine in CLL (Contantine Tam, Peter MacCallum Cancer Centre, St Vincent's Hospital and University of Melbourne, Australia) |
|||||
| The Clinical Management of FLT3-Mutated AML (Mark Levis, Johns Hopkins School of Medicine, USA) |
|||||
| 15:20 - 15:40 | Coffee Break | ||||
| 15:40 - 17:00 | EHA-KSH Joint Symposium 1 | Special Report 01 | |||
| Myelodysplastic Syndrome | Updates on Cellular Therapies | ||||
| The Best Prediction of Prognosis for MDS: How to Integrate Clinical and Molecular Data (Valeria Santini, Univ. of Florence, Italy) |
|
||||
| Clinical Effects of Somatic Mutations in MDS (Je-Hwan Lee, Univ. of Ulsan, Korea) |
|||||
| Pathogenesis and Management of CMMoL (Raphael Itzykson, Paris Diderot Univ., France) |
|||||
| Hypomethylating Therapy in Stem Cell Transplantation for MDS (Yoo-Jin Kim, The Catholic Univ., Korea) |
|||||
| 17:00 - 17:10 | Break | ||||
| 17:10 - 18:10 | Oral Presentation 07 | Oral Presentation 08 | Oral Presentation 09 | ||
| 18:10 - 18:40 | Poster Presentation 01(Place: Exhibition Hall, B3) | ||||
| 18:40 - 20:00 | Welcome Reception (Place: Vista Hall Lobby, B2) |
||||
March 30 (Friday)
| VISTA 1 | VISTA 2 | VISTA 3 | |
|---|---|---|---|
| 08:00 - 09:00 | Oral Presentation 10 | Oral Presentation 11 | Oral Presentation 12 (KOR) |
| 09:00 - 10:20 | Scientific Session 03 | Scientific Session 04 | Oral Presentation 13 |
| Recent Advances in Acute Promyelocytic Leukemia | Recent Advances in Natural Killer T-cell Lymphoma | ||
| JALSG Prospective Study for APL (Akihiro Takeshita, Hamamatasu Univ. School of Medicine, Japan) |
Molecular Pathogenesis of NKTL (Wee Joo Chng, National Univ. Cancer Institute, Singapore) |
||
| Therapy of APL (Lionel Ades, des Universités-Praticien Hospitalier, France) |
Recent Advances in NK/T-Cell Lymphoma (Yok Lam Kwong, Univ. of Hong Kong, Hong Kong) |
||
| Strategies to Define High-risk Patients in APL (Byung-Sik Cho, The Catholic Univ. of Korea, Korea) |
Beyond Current Standard Care of ENKTL (Won Seog Kim, Samsung Medical Center, Korea) |
||
| 10:20 - 10:30 | Break | ||
| 10:30 - 11:50 | Plenary Lecture 02 | ||
| Targeting Leukemic Stem Cells | |||
| Human Myeloid Leukemia Stem Cells (Koichi Akashi, Kyushu Univ. Graduate School of Medical Sciences, Japan) |
|||
| Pre-Cancerous Stem Cells in MDS and AML: Significance, Mechanisms, and Therapeutic Targeting (Ulrich Steidl, Albert Einstein College of Medicine, USA) |
|||
| 11:50 - 12:00 | Break | ||
| 12:00 - 13:00 | [Luncheon] Satellite Symposium 04 AMGEN |
[Luncheon] Satellite Symposium 05 BMS |
[Luncheon] Satellite Symposium 06 HANDOK |
| Treatment of Multiple Myeloma in Relapse Keith Stewart (Mayo Clinic, USA) |
Emerging Trends in CML Management Elias Jabbour (Leukemia Department, MD Anderson Cancer Center, USA) |
HSCT Early Complications: Focus on Severe Hepatic Veno-occlusive Disease; - The Revised EBMT Diagnostic and Severity Criteria for Adults and an Update on Defibrotide. Mohamad Mohty (Clinical Hematology and Cellular Therapy Dpt., Sorbonne University, Hopital Saint-Antoine, France) |
|
| 13:00 - 14:20 | Scientific Session 05 | Scientific Session 06 | Scientific Session 07(KSH-KOGO Joint) |
| Cell Death Mechanism | Bone Marrow Failure syndrome | Cancer Genomics | |
| Apoptotic Cell Death (Soo Youl Kim, National Cancer Center, Korea) |
Non-Transplant Therapy for Bone Marrow Failure (Danielle Townsley, Clinical Development ? Oncology, Medimmune LLC, USA) |
Variability in Chromatin Architecture and Associated DNA Repair at Genomic Positions Containing Somatic Mutations (Seon-Young Kim, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Korea) |
|
| CHIP Controls Necroptosis Through Ubiquitylation- and Lysosome-dependent Degradation of RIPK3 (Jaewhan Song, Yonsei Univ., Korea) |
Role of Microenvironment and Genetics in BM Failure (Myungshin Kim, The Catholic Univ. of Korea, Korea) |
Deciphering the Cell-of-Origin Harboring Driver Mutations in Brain Tumors (Jeong-Ho Lee, Korea Advanced Institute of Science and Technology (KAIST), Korea) |
|
| Functional Isolation of New Modulators in Apoptosis and Necroptosis (Yong-Keun Jung, Seoul National Univ., Korea) |
Inherited BM Failure Syndrome (Hoon Kook, Chonnam National Univ. Medical School, Korea) |
Contribution of Germline Variants in Pan-Cancer Development (Youngil Koh, Seoul National Univ., Korea) |
|
| Developing a Genetic Data based Prognostic Model for Hematologic Cancer (SeungHyun Jung, The Catholic Univ., Korea) |
|||
| 14:20 - 14:40 | Coffee Break | ||
| 14:40 - 15:40 | Asian Hematology Network: JSH-KSH Joint Symposium
Explore Deep Inside the Asian Hematology Network |
Satellite Symposium 07 ROCHE |
|
| A Novel Mechanism of Cancer Immune Evasion in Human Cancers (Seishi Ogawa, Kyoto Univ., Japan) |
Advancing Value Based Approaches in the Treatment of NHL: Contemporary Strategies and Innovations
(Hyeon-seok Eom, National Cancer Center, Korea) |
||
| AML Prognosis based on Clinical and Genomic Data (Hyeoung-Joon Kim, Chonnam National Univ. Medical School, Korea) |
|||
| 15:40 - 17:00 | EHA-KSH Joint Symposium 02 | Special Report 02 | |
| Aplastic Anemia - Paroxysmal Nocturnal Hemoglobinuria | Multiple Myeloma Niche | ||
| Diagnosis and Management of AA and Refractory Cytopenia of Childhood
(Department of Paediatrics and Adolescent Medicine, University Children's Hospital, Freiburg, Germany) |
Clinical Implications of MRD in Multiple Myeloma
(Wee Joo Chng, National Univ. Cancer Institute, Singapore) |
||
| Frontline Alternative Donor SCT Versus Immunosuppressive Treatment for Children with Severe AA Who Lack Matched Related Donor
(Hyoung Jin Kang, Seoul National Univ., Korea) |
The Ubiquitin-Proteasome Pathway : Friend and Foe in Multiple Myeloma (Robert Orlowski, The Univ. of Texas MD Anderson Cancer Center (MDACC), USA) |
||
| An Update on the Management of PNH (Anita Hill, St. James's Univ. Hospital, UK) |
Cellular Immunotherapy in Multiple Myeloma (Je-Jung Lee, Chonnam National Univ. Hwasun Hospital, Korea) |
||
| Clinical Implications of Renal Dysfunction in Patients with PNH (Jin Seok Kim, Yonsei Univ., Korea) |
|||
| 17:00 - 17:10 | Break | ||
| 17:10 - 17:50 | Best Abstract Presentation | Satellite Symposium 08 TAKEDA | |
| RAG1 High Expression Associated with IKZF1 Dysfunction in B-cell Acute Lymphoblastic Leukemia (Zheng Ge, Zhongda Hospital, China) Decision Supporting Tool for Thrombotic Microangiopathy Based on Machine Learning Technique (Youngil Koh, Seoul National University Hospital, Korea) Aberrant ARID5Bexpression and IKAROS Regulation in ALL (Chunhua Song, Pennsylvania State Univ, USA) |
Novel Treatment Strategies for Multiple Myeloma: A Focus on Oral Proteasome Inhibitors (Antonio Palumbo, Italy) |
||
| 17:50 - 18:20 | Poster Presentation 02 (Place: Exhibition Hall, B3) | ||
| 18:20 - 20:00 | Gala Dinner (Place: Walkerhill Theater, B1) |
||
March 31 (Saturday)
| VISTA 1 | VISTA 2 | VISTA 3 | |
|---|---|---|---|
| 08:30 - 09:30 | Oral Presentation 14 | Oral Presentation 15 | Oral Presentation 16 (KOR) |
| 09:30-10:50 | Scientific Session 08 | Scientific Session 09 | Oral Presentation 17 |
| Current Progress in Pediatric Acute Leukemia | Detetion of Minimal Residual Disease in Hematologic Malignancy | ||
| New Developments in the Treatment of Newly Diagnosed and Relapsed ALL (Stephen Hunger, Children's Hospital of Philadelphia, USA) |
MRD Detection in Acute Leukemia, CLL and Multiple Myeloma (Alberto Orfao, Univ. of Salamanca (USAL), Spain) |
||
| Therapy Optimization in Infant ALL (Daisuke Tomizawa, National Center for Child Health and Development, Japan) |
NGS-based Assessment of Clonality & MRD Determination in ALL (In-Suk Kim, Pusan National Univ. Yangsan Hospital, Korea) |
||
| Genomic Landscape and Therapy Optimization of Pediatric Mixed Phenotype Acute Leukemia (Hiroto Inaba, St. Jude Children's Research Hospital, USA) |
Selected Short Talk I Development and Preliminary Evaluation of Customized pan-Blood Cancer NGS Panel (Jun Hyung Lee, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Korea) |
||
| Selected Short Talk II Evaluation of Two Commercial Kits for Flow Cytometric MRD Detection in B-ALL (Ari Ahn, University of Ulsan College of Medicine and Asan Medical Center, Korea) |
|||
| 10:50 - 11:10 | Coffee Break | ||
| 11:10 - 12:30 | Plenary Lecture 03 | ||
| Development of Precision Medicine Trials | |||
| Development of Precision Medicine Trials for ALL (Stephen Hunger, Children's Hospital of Philadelphia, USA) |
|||
| Progress in Therapy of Philadelphia Positive ALL (Farhad Ravandi, MD Anderson Cancer Center, USA) |
|||
| 12:30 - 13:00 | Working Party Reports | ||
| 13:00 - 13:30 | Award Ceremony & Closing Meeting | ||
